Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PRICE-FIXING GRAND JURY INVESTIGATIONS IN PHILADELPHIA are underway on two separate fronts according to recent financial disclosures by Robins and SmithKline. Robins said that a federal grand jury in the city subpoenaed the firm's records, due Dec. 30, as part of an industry-wide probe into alleged price-fixing of prefilled syringes. Information on the subpoena was made public as part of Robins' filing for Chapter 11 bankruptcy relief from Dalkon Shield litigation. SmithKline said a federal grand jury in Philadelphia is continuing to investigate alleged antitrust violations related to marketing of its antibiotic Ancef. The firm reported the grand jury is examining "the marketing, sale, and distribution of Ancef (cefazolin) in the U.S. between Jan. 1, 1980 and June 1, 1985, particularly as those practices relate to bids and sales to hospitals and hospital buying groups." The disclosure was made in a Securities & Exchange Commission (SEC) filing, which detailed a proposed share buy-back ("The Pink Sheet" Dec. 1, T&G-3). Earlier in the year, Lilly revealed that its marketing of Kefzol (cefazolin) is the subject of an ongoing grand jury investigation in Philadelphia. Lilly made the disclosure in an SEC filing related to the purchase of Hybritech ("The Pink Sheet" Feb. 17, T&G-2). LyphoMed received the first ANDA for a generic version of cefazolin on Nov. 17 ("The Pink Sheet" Dec. 1, T&G-10).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts